The company said, “Revenues for Q3 2025 increased by 32% to $14.3M compared to $10.8M in Q2 2025, primarily due to: A strong increase of $2.1M in rapid HIV test sales to $3.6M in Q3 2025, driven by renewed UniGold HIV rapid test demand and the resumption of TrinScreen HIV sales under the new manufacturing model; and A significant rise in haemoglobin product sales, rising to $5.7M compared to $4M in Q2 2025.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRIB:
- Trinity Biotech awarded order for 9M TrinScreen HIV tests
- Trinity Biotech Accelerates Global Rollout of High-Capacity HbA1c Column System After New Regulatory Clearances
- Trinity Biotech expands global rollout of high-capacity column system
- Trinity Biotech Secures WHO Approval for Offshore Manufacturing of HIV Test
- Trinity Biotech Collaborates to Enhance Prostate Cancer Test